TYR and melanoma: In a distinct study by Choi et al., treatment of HM3KO melanoma cells with deoxynojirimycin, a α-glucosidase inhibitor that disrupts early ER N-glycan processing, and deoxymannojirimycin, an inhibitor of α-1,2-mannosidase which are thought to be responsible for late glycan processing, showed inhibition of glycosylation, transportation of tyrosinase to the melanosome and melanin synthesis [42].